EN

Supporting Local Diversity! Formosa Pharma Sponsors Taipei Bravo PlayOne Women’s Football Team

ESG / By

08/21/2025 Formosa Pharmaceuticals is proud to announce its official sponsorship of the Taipei Bravo PlayOne Women’s Football Team, reinforcing the company’s commitment to ESG principles—particularly in the areas of gender equality, community engagement, and health promotion. As part of this partnership, the team’s official 2025–2026 season jerseys will prominently feature the Formosa Pharmaceuticals logo and …

Supporting Local Diversity! Formosa Pharma Sponsors Taipei Bravo PlayOne Women’s Football Team Read More »

Formosa Pharma x Chingcheng Attorney at Law – Employee Legal Education Training

ESG / By

05/14/2025 Formosa Pharmaceuticals invited the legal team from Chingcheng Attorney at Law to conduct an employee legal education training at our Taipei office. We extend our sincere thanks to Founding Partner James Hou, along with Attorneys Jim Huang, Louis He, and Alice Yang, for delivering a well-crafted and engaging session. The training offered practical legal …

Formosa Pharma x Chingcheng Attorney at Law – Employee Legal Education Training Read More »

Formosa Pharma Family Day – A Gathering at Wen Sun Farm, Xindian

ESG / By

05/10/2025 Formosa Pharma’s Family Day was held with great enthusiasm at Wen Sun Farm in Xindian! Employees joined the event with their beloved family members, enjoying a day filled with camping, team-building games, DIY crafts, and shared meals to strengthen bonds. During the farm’s signature ecological tour, employees and their families also experienced tea picking …

Formosa Pharma Family Day – A Gathering at Wen Sun Farm, Xindian Read More »

Dialogue in the Dark! Formosa Pharma’s In-Depth Dialogue & Listening

ESG / By

02/08/2025 As part of its commitment to corporate sustainability, Formosa Pharmaceuticals has integrated ESG principles into its operations and organized a Dialogue in the Dark (DiD) workshop for employees. This initiative promotes employee well-being and aligns with the United Nations Sustainable Development Goal (SDG) 4 – Quality Education. As a leader in ophthalmic pharmaceuticals, the …

Dialogue in the Dark! Formosa Pharma’s In-Depth Dialogue & Listening Read More »

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

News / By

TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery, will be presented at the 2022 Association for …

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting Read More »

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007

News / By

(Corticosteroid for inflammation and pain after cataract surgery) TAIPEI – June 3, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code:6838) and China Grand Pharma (“Grand”, HKG stock code:00512) announce that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the territory defined by Mainland China, Hong Kong, and …

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007 Read More »

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital

News / By

April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has successfully completed a Series C financing round, increasing its cash capital by NTD $600 million (approx. USD $21.1 million). In addition to the continuous support from major shareholder, Formosa Laboratories, numerous prominent venture capital firms participated in this round of capital …

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital Read More »

APP13007 completes Phase 2 clinical trial and EOP2 meeting.

News / By

Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract surgery. The End-of-Phase 2 meeting with the FDA is successful, setting the stage for pivotal Phase 3 trials to begin as early as 2020-Q4. APP13007 meets primary endpoints demonstrating rapid …

APP13007 completes Phase 2 clinical trial and EOP2 meeting. Read More »

Scroll to Top